Hayashida Kazutaka, Kume Noriaki, Murase Takatoshi, Minami Manabu, Nakagawa Daisuke, Inada Tsukasa, Tanaka Masaru, Ueda Akira, Kominami Goro, Kambara Hirofumi, Kimura Takeshi, Kita Toru
Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Circulation. 2005 Aug 9;112(6):812-8. doi: 10.1161/CIRCULATIONAHA.104.468397. Epub 2005 Aug 1.
Markers of cardiac injury, including troponin-T (TnT), are used to diagnose acute coronary syndrome (ACS); however, markers for plaque instability may be more useful for diagnosing ACS at the earliest stage. Lectin-like oxidized LDL receptor-1 (LOX-1) appears to play crucial roles in the pathogenesis of atherosclerotic plaque rupture and ACS onset. LOX-1 is released in part as soluble LOX-1 (sLOX-1) by proteolytic cleavage.
We examined serum sLOX-1 levels in 521 patients, consisting of 427 consecutive patients undergoing coronary angiography, including 80 ACS patients, 173 symptomatic coronary heart disease patients, 122 patients with significant coronary stenosis without ischemia, and 52 patients without apparent coronary atherosclerosis plus 34 patients with noncardiac acute illness and 60 patients with noncardiac chronic illness. Time-dependent changes in sLOX-1 and TnT levels were analyzed in an additional 40 ACS patients. Serum sLOX-1 levels were significantly higher in ACS than the other groups and were associated with ACS as shown by multivariable logistic regression analyses. Given a cutoff value of 1.0 ng/mL, sLOX-1 can discriminate ACS from other groups with 81% and 75% of sensitivity and specificity, respectively. sLOX-1 can also discriminate ACS without ST elevation or abnormal Q waves and ACS without TnT elevation from non-ACS with 91% and 83% of sensitivity, respectively. Peak values of sLOX-1 in ACS were observed earlier than those of TnT.
sLOX-1 appears to be a useful marker for early diagnosis of ACS.
包括肌钙蛋白T(TnT)在内的心脏损伤标志物用于诊断急性冠状动脉综合征(ACS);然而,斑块不稳定性标志物可能对早期诊断ACS更有用。凝集素样氧化型低密度脂蛋白受体1(LOX-1)似乎在动脉粥样硬化斑块破裂和ACS发病机制中起关键作用。LOX-1部分通过蛋白水解裂解以可溶性LOX-1(sLOX-1)形式释放。
我们检测了521例患者的血清sLOX-1水平,其中包括427例连续接受冠状动脉造影的患者,包括80例ACS患者、173例有症状冠心病患者、122例有明显冠状动脉狭窄但无缺血的患者、52例无明显冠状动脉粥样硬化的患者,另外还有34例非心脏急性疾病患者和60例非心脏慢性疾病患者。在另外40例ACS患者中分析了sLOX-1和TnT水平的时间依赖性变化。多变量逻辑回归分析显示,ACS患者的血清sLOX-1水平显著高于其他组,且与ACS相关。给定截断值为1.0 ng/mL时,sLOX-1分别以81%的敏感性和75%的特异性区分ACS与其他组。sLOX-1还能分别以91%和83%的敏感性区分无ST段抬高或异常Q波的ACS以及无TnT升高的ACS与非ACS。ACS中sLOX-1的峰值比TnT出现得更早。
sLOX-1似乎是ACS早期诊断的有用标志物。